Avian Colibacillosis and Septicemia (Avian Pathogenic Escherichia coli - APEC / Colisepticemia)

Avian colibacillosis is a complex infectious disease of poultry caused by avian pathogenic Escherichia coli (APEC), a subset of E. coli strains possessing specific virulence factors that enable colonization and invasion of the respiratory and intestinal tracts, leading to localized or systemic infections. The disease manifests in various forms, including acute septicemia (colisepticemia), respiratory tract infection (airsacculitis, pneumonia), pericarditis, perihepatitis, salpingitis, peritonitis, cellulitis (gangrenous dermatitis), omphalitis (yolk sac infection), and coligranuloma (Hjarre's disease). Colisepticemia is the most severe systemic form, characterized by rapid onset of bacteremia, endotoxemia, and multi-organ failure, often resulting in high morbidity and mortality. The disease affects all poultry sectors—broilers, commercial layers, broiler breeders, turkeys, ducks, and backyard flocks—and is a leading cause of economic losses worldwide due to mortality, decreased feed conversion efficiency, increased carcass condemnation at processing, and reduced egg production. In broilers, colibacillosis is frequently secondary to viral respiratory infections (e.g., infectious bronchitis, Newcastle disease) or environmental stressors, while in layers, it often presents as salpingitis and peritonitis, particularly in cage systems. The global poultry industry relevance is underscored by its endemic nature, with prevalence rates varying from 10% to 50% in affected flocks, and its role as a major contributor to antimicrobial resistance due to extensive antibiotic use.

The primary causative agent is avian pathogenic Escherichia coli (APEC), a Gram-negative, facultative anaerobic bacillus belonging to the family Enterobacteriaceae. APEC strains are characterized by a distinct set of virulence-associated genes, including those encoding adhesins (e.g., F1 and P fimbriae, curli fibers, and autotransporter adhesins such as AatA and Ag43), iron acquisition systems (e.g., aerobactin, salmochelin, and yersiniabactin), protectins (e.g., lipopolysaccharide O-antigen, capsule K1, and outer membrane proteins), and toxins (e.g., hemolysins, cytotoxic necrotizing factor 1, and vacuolating autotransporter toxin). Common serogroups associated with avian colibacillosis include O1, O2, O18, O78, and O111, with O78 being the most frequently isolated in many regions. The bacterium's pathogenicity is mediated by endotoxin (lipopolysaccharide, LPS), which triggers a severe inflammatory response, and by the ability to resist serum complement and phagocytosis. APEC strains are genetically diverse and often carry plasmids (e.g., ColV plasmids) that harbor multiple virulence genes. The disease is not caused by a single clone but by a heterogeneous population of strains, which complicates vaccine development. In addition to E. coli, other bacterial agents such as Pasteurella multocida, Gallibacterium anatis, and Ornithobacterium rhinotracheale can cause similar lesions, but APEC is the primary etiological agent. The bacterium is ubiquitous in poultry environments, surviving in litter, dust, and water, and can persist for months under favorable conditions.

Avian colibacillosis is a worldwide endemic disease, with prevalence varying by poultry sector, management practices, and geographical region. In broilers, the disease is most common between 3 and 6 weeks of age, with morbidity ranging from 5% to 30% and mortality from 2% to 20%, depending on the presence of predisposing factors. In commercial layers, colibacillosis often occurs during peak egg production (25-40 weeks) and can cause a 5-15% drop in egg production, with mortality up to 5%. Broiler breeders are similarly affected, with salpingitis and peritonitis being common sequelae. Turkeys are highly susceptible, with colisepticemia causing significant losses, especially in young poults (1-4 weeks). Ducks and geese are also affected, often with a higher incidence of respiratory and systemic disease. Housing systems play a critical role: birds in high-density, poorly ventilated houses with high ammonia levels are at increased risk. Deep litter systems with wet litter and poor litter quality predispose to footpad dermatitis and cellulitis. Free-range and backyard flocks may have lower incidence but can suffer outbreaks due to contaminated water sources. Seasonality is observed, with higher incidence in winter months when ventilation is reduced to conserve heat, leading to poor air quality. Wild birds, rodents, and insects can serve as mechanical vectors, introducing APEC into flocks. Biosecurity lapses, such as inadequate cleaning and disinfection between flocks, contaminated feed or water, and movement of personnel and equipment, are major risk factors. The disease is often secondary to primary viral infections (e.g., infectious bronchitis virus, Newcastle disease virus, avian influenza virus) or mycoplasma infections (e.g., Mycoplasma gallisepticum, M. synoviae), which damage the respiratory epithelium and facilitate E. coli invasion. Immunosuppressive conditions, such as infectious bursal disease or chicken infectious anemia, also increase susceptibility. Flock morbidity and mortality are influenced by the virulence of the APEC strain, the immune status of the birds, and the speed of intervention. Feed conversion ratio (FCR) is adversely affected, with affected broilers showing a 5-10% increase in FCR, and egg production losses in layers can be permanent if salpingitis is severe.

The pathogenesis of avian colibacillosis begins with colonization of the upper respiratory tract or intestine by APEC. The bacterium adheres to epithelial cells via fimbriae and other adhesins, then invades the mucosal barrier. In respiratory colibacillosis, the primary route is inhalation of contaminated dust or aerosols, often following damage to the respiratory epithelium by viral or mycoplasmal infections. Once in the lungs, APEC multiplies and spreads to the air sacs, causing airsacculitis. The bacteria then enter the bloodstream, leading to bacteremia and septicemia. The systemic spread is facilitated by the bacterium's ability to resist complement-mediated lysis and phagocytosis, due to the presence of capsular polysaccharides and outer membrane proteins. Endotoxin (LPS) released from the bacterial cell wall triggers a massive inflammatory response, with release of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), leading to fever, vasodilation, increased vascular permeability, and disseminated intravascular coagulation. This results in the characteristic lesions of fibrinous pericarditis, perihepatitis, and airsacculitis, as fibrin is deposited on serosal surfaces. In the liver, bacterial emboli cause multifocal necrosis and inflammation. In the spleen, lymphoid depletion and necrosis occur. The bacteria can also localize in the reproductive tract, causing salpingitis and peritonitis in layers, often via ascending infection from the cloaca. In young chicks, omphalitis occurs when the yolk sac is contaminated, leading to septicemia. The intestinal form, though less common, involves enteritis and diarrhea due to enterotoxin production and mucosal damage. The severity of the disease is dose-dependent and influenced by the virulence factors of the strain. The incubation period is typically 24-72 hours after exposure. The disease can be acute, with death occurring within 24-48 hours of clinical signs, or chronic, with localized lesions such as coligranuloma (Hjarre's disease), which is characterized by granulomatous lesions in the liver, cecum, and other organs.

Intrinsic factors include genetic susceptibility, as some broiler lines are more prone to respiratory disease and colibacillosis. Age is a critical factor, with young birds (1-6 weeks) being more susceptible due to immature immune systems. High production stress in layers and breeders, such as peak egg production, can compromise immunity. Immunosuppression from concurrent infections (e.g., infectious bursal disease virus, chicken anemia virus, Marek's disease) or stress (e.g., heat, cold, overcrowding) increases susceptibility. Extrinsic factors are numerous: poor biosecurity, including inadequate cleaning and disinfection, allowing APEC to persist in the environment; high stocking density, which increases ammonia and dust levels, damaging the respiratory tract; poor ventilation, leading to high ammonia (>25 ppm) and carbon dioxide levels; wet litter, which promotes bacterial growth and footpad lesions; contaminated feed or water, especially with fecal material; vaccination failures, particularly against respiratory viruses, leaving birds vulnerable; and concurrent viral or mycoplasma infections that damage the respiratory epithelium. Nutritional deficiencies, such as vitamin A or E deficiency, can impair mucosal integrity and immune function. Environmental stressors, such as temperature fluctuations, drafts, and noise, can also predispose to disease. Management practices, such as beak trimming, vaccination, and handling, can cause stress and increase susceptibility. In layers, the onset of lay is a high-risk period due to the stress of egg production and the opening of the cloaca, facilitating ascending infections.

Clinical signs of avian colibacillosis vary depending on the form and severity. In acute septicemia, birds may be found dead without prior signs, especially in young chicks. In less acute cases, affected birds show depression, lethargy, huddling, ruffled feathers, and reduced feed and water intake. Respiratory signs include dyspnea, gasping, coughing, sneezing, and rales, often accompanied by nasal discharge and conjunctivitis. Facial edema and swelling of the wattles and combs may be observed. Cyanosis of the comb and wattles can occur in severe septicemia due to poor oxygenation. Diarrhea is common, with feces being watery, yellowish, or greenish, and may contain mucus or blood. In layers, a sudden drop in egg production (5-15%) is typical, with eggs showing shell abnormalities such as rough, thin, or misshapen shells, and decreased internal egg quality. Salpingitis and peritonitis may cause birds to assume a penguin-like posture due to abdominal distension. Neurological signs, such as torticollis, opisthotonos, and paralysis, can occur if the bacteria invade the central nervous system, though this is rare. In chronic cases, birds may become emaciated and show lameness due to arthritis or osteomyelitis. Omphalitis in chicks presents as yolk sac infection, with swollen, inflamed navels and a foul-smelling discharge. Cellulitis, often seen in broilers, presents as subcutaneous swelling and necrosis, typically on the abdomen and thighs, and is detected at processing. The flock-level signs include increased mortality, uneven growth, and poor uniformity. The severity and duration of clinical signs depend on the virulence of the strain, the immune status of the flock, and the presence of predisposing factors.

Differential diagnoses for avian colibacillosis include: 1) Fowl cholera (Pasteurella multocida): Similar septicemic lesions, but fowl cholera often causes sudden death in older birds, with petechial hemorrhages on the heart and liver, and the organism is a Gram-negative bipolar-staining coccobacillus. Culture and biochemical tests differentiate. 2) Mycoplasmosis (Mycoplasma gallisepticum, M. synoviae): Respiratory signs and airsacculitis, but typically less severe systemic lesions; serology (ELISA, HI) and PCR are used for differentiation. 3) Infectious bronchitis (IBV): Respiratory signs and nephritis, but no fibrinous polyserositis; virus isolation and PCR confirm. 4) Newcastle disease (NDV): Respiratory and neurological signs, with characteristic hemorrhagic lesions in the proventriculus and cecal tonsils; HI test and PCR differentiate. 5) Avian influenza (HPAI): Severe systemic disease with cyanosis, edema, and hemorrhages; virus isolation and PCR are definitive. 6) Ornithobacterium rhinotracheale (ORT): Respiratory disease with airsacculitis and pneumonia, but typically less systemic; culture on blood agar with CO2. 7) Gallibacterium anatis: Causes salpingitis and peritonitis in layers, similar to colibacillosis; culture and MALDI-TOF differentiate. 8) Erysipelas (Erysipelothrix rhusiopathiae): Septicemia with skin lesions, but more common in turkeys; culture and Gram stain. 9) Coccidiosis (Eimeria spp.): Intestinal lesions and diarrhea, but no systemic fibrinous lesions; fecal floatation and lesion scoring. 10) Aspergillosis: Respiratory signs and granulomatous lesions in lungs and air sacs, but fungal hyphae on histopathology. Differentiation relies on bacterial culture, PCR, serology, and characteristic necropsy lesions.

The diagnostic approach for avian colibacillosis follows a systematic algorithm: 1) Flock history: Assess age, clinical signs, mortality pattern, vaccination history, and recent stressors. 2) Clinical observation: Examine birds for depression, respiratory distress, diarrhea, and egg production drops. 3) Gross necropsy: Perform necropsy on multiple affected birds, noting characteristic lesions such as fibrinous pericarditis, perihepatitis, airsacculitis, salpingitis, and omphalitis. 4) Sample collection: Aseptically collect samples from liver, spleen, heart blood, air sacs, and yolk sac for bacterial culture. Also collect tracheal and cloacal swabs for PCR and virus isolation. 5) Bacterial culture: Inoculate samples on MacConkey agar and blood agar; incubate aerobically at 37°C for 24-48 hours. Identify E. coli by colony morphology, Gram stain, and biochemical tests (e.g., IMViC). 6) Serotyping: Determine O and K antigens using specific antisera. 7) Molecular diagnostics: Perform PCR for virulence genes (e.g., iss, iucC, papC, tsh) to confirm APEC pathotype. 8) Serology: Collect serum samples for ELISA to detect antibodies against E. coli, though this is not routinely used for diagnosis. 9) Histopathology: Fix tissues in formalin for microscopic examination to confirm lesions and rule out other causes. 10) Antimicrobial susceptibility testing: Perform disk diffusion or broth dilution to guide treatment. 11) Rule out primary pathogens: Test for respiratory viruses (IBV, NDV, AIV) and mycoplasmas using PCR and serology. 12) Final diagnosis: Based on isolation of APEC from systemic sites, characteristic lesions, and exclusion of other causes.

Serology: ELISA can detect antibodies against E. coli, but titers are not diagnostic due to widespread exposure. HI titers are not applicable. Molecular diagnostics: PCR assays targeting virulence genes (e.g., iss, iucC, papC, tsh) are used to identify APEC. Real-time PCR can quantify bacterial load. Microbiology: Isolation of E. coli from liver, spleen, or heart blood on MacConkey agar yields pink colonies (lactose fermenters). On blood agar, colonies are gray, mucoid, and may be hemolytic. Biochemical tests: Indole positive, Methyl red positive, Voges-Proskauer negative, Citrate negative (IMViC + + - -). Serotyping: Agglutination with O and K antisera. Coccidiosis lesion scoring: Not applicable unless concurrent coccidiosis; use Johnson & Reid 0-4 scale. Mycotoxin feed assays: Not directly relevant, but may be performed to rule out immunosuppression. Blood chemistry/CBC: In septicemia, leukocytosis with heterophilia, and elevated liver enzymes (AST, ALT) due to hepatic damage. Blood cultures can be positive for E. coli.

Radiography: Not commonly used in poultry, but may reveal airsacculitis as increased opacity in thoracic cavity, or hepatomegaly. Ultrasonography: Can be used in layers to detect fluid in the abdominal cavity due to peritonitis, but is not standard. Gross necropsy photography: Essential for documentation; characteristic lesions include fibrinous exudate on the heart (pericarditis), liver (perihepatitis), and air sacs (airsacculitis). The liver may be swollen and congested, with a greenish or bronze discoloration. The spleen is often enlarged and mottled. In chronic cases, granulomatous lesions (coligranuloma) may be seen in the liver and cecum.

Gross necropsy lesions: Fibrinous pericarditis (thickened, opaque pericardium with yellow fibrinous exudate), perihepatitis (fibrinous coating on liver surface), airsacculitis (thickened, cloudy air sacs with caseous exudate), peritonitis (fibrinous exudate in abdominal cavity), salpingitis (inflamed oviduct with caseous material), omphalitis (inflamed yolk sac with necrotic debris), and cellulitis (subcutaneous caseous exudate). Histopathology: Microscopic examination reveals fibrinous inflammation with heterophilic infiltration, necrosis, and bacterial colonies. In the liver, multifocal coagulative necrosis and heterophilic infiltration are seen. The heart shows fibrinous pericarditis with edema and inflammatory cells. The air sacs have thickened epithelium with fibrin deposition and bacterial aggregates. In the spleen, lymphoid depletion and necrosis are present. In chronic cases, granulomatous inflammation with central necrosis and surrounding macrophages and giant cells is observed. Special stains, such as Gram stain, can demonstrate Gram-negative bacilli.

Treatment of avian colibacillosis involves antimicrobial therapy, supportive care, and management changes. Antimicrobials should be selected based on culture and sensitivity testing, as resistance is common. Common antibiotics include: Amoxicillin (10-20 mg/kg body weight orally, or 100-200 g/ton feed, for 3-5 days), Oxytetracycline (10-20 mg/kg, or 200-400 g/ton feed, for 3-5 days), Tylosin (10-20 mg/kg, or 100-200 g/ton feed, for 3-5 days), Tilmicosin (15-20 mg/kg, or 200-400 g/ton feed, for 3-5 days), Enrofloxacin (10 mg/kg, or 100-200 g/ton feed, for 3-5 days; note legal restrictions in some countries), Florfenicol (20-30 mg/kg, or 200-400 g/ton feed, for 3-5 days). Drinking water administration is often preferred for rapid treatment; typical concentrations are 100-200 mg/L for amoxicillin, 200-400 mg/L for oxytetracycline, and 100-200 mg/L for enrofloxacin. Withdrawal times must be observed. Supportive therapy includes vitamins (A, D3, E, C, K) and electrolytes in water to reduce stress and improve immune function. Probiotics and organic acids may be used to support gut health. In severe outbreaks, culling of severely affected birds may be necessary. Biosecurity measures should be intensified, including cleaning and disinfection of water lines, reducing stocking density, improving ventilation, and addressing predisposing factors. Vaccination of future flocks with autogenous or commercial E. coli vaccines may be considered, though efficacy is variable. Anti-inflammatory drugs (e.g., aspirin) may be used to reduce fever and inflammation, but are not commonly used in poultry.

The prognosis for avian colibacillosis depends on the severity of the outbreak, the speed of intervention, and the presence of underlying causes. In acute septicemia with high mortality, the prognosis is poor, and mortality can reach 20% or more if untreated. With prompt antimicrobial therapy and management corrections, mortality can be reduced to 2-5%. In layers, egg production may recover to near normal levels within 2-4 weeks, but if salpingitis is severe, permanent production losses can occur. In broilers, affected flocks may have increased FCR and reduced weight gain, leading to economic losses. The prognosis is better in flocks with localized infections (e.g., omphalitis) if treated early. Chronic cases, such as coligranuloma, are often refractory to treatment and may require culling. The overall flock recovery rate is typically 80-90% with appropriate therapy, but the disease can recur if predisposing factors are not corrected. In severe outbreaks, depopulation may be considered, especially if the disease is complicated by other pathogens.

Following an outbreak, a structured monitoring plan is essential. Conduct serial necropsies of any dead birds to monitor resolution of lesions. Perform bacterial culture and sensitivity testing on samples from recovered birds to ensure clearance. Monitor flock performance indicators, such as mortality, feed consumption, and egg production, for at least 2 weeks after treatment. Implement enhanced biosecurity measures, including thorough cleaning and disinfection of the facility, water lines, and equipment. Review and improve ventilation, litter management, and stocking density. Conduct serological monitoring for concurrent viral infections (e.g., IBV, NDV) to assess immune status. For layers, monitor egg quality and production recovery. In broiler breeders, monitor fertility and hatchability. Implement a vaccination program for future flocks, including live or inactivated E. coli vaccines if available. Schedule regular audits of biosecurity protocols and adjust as needed. Maintain records of antimicrobial use and withdrawal times to ensure compliance with regulations.

Pearls: 1) Always perform necropsy on multiple birds to identify characteristic fibrinous polyserositis, which is highly suggestive of colibacillosis. 2) Culture from systemic sites (liver, spleen, heart blood) is essential for definitive diagnosis; avoid culturing from the intestine. 3) Colibacillosis is often secondary to respiratory viruses; always test for IBV, NDV, and mycoplasma. 4) In layers, salpingitis and peritonitis are common; examine the oviduct for caseous exudate. 5) Antimicrobial resistance is common; always perform culture and sensitivity before treatment. 6) Improve ventilation and reduce ammonia to prevent respiratory damage. Pitfalls: 1) Do not rely solely on clinical signs, as they are nonspecific. 2) Avoid using antibiotics without sensitivity testing, as this can lead to resistance and treatment failure. 3) Do not overlook predisposing factors; treating the bacterial infection without addressing management issues will lead to recurrence. 4) Do not confuse colibacillosis with fowl cholera or other septicemic diseases; laboratory confirmation is crucial. 5) In broilers, cellulitis may be detected only at processing; implement measures to reduce skin contamination. 6) Do not use enrofloxacin in countries where it is banned in poultry due to public health concerns.

Antimicrobial protocols based on Plumb's Veterinary Drug Handbook and AAAP guidelines: Amoxicillin: 10-20 mg/kg PO q12h, or 100-200 g/ton feed, or 100-200 mg/L drinking water, for 3-5 days; withdrawal 7 days. Oxytetracycline: 10-20 mg/kg PO, or 200-400 g/ton feed, or 200-400 mg/L water, for 3-5 days; withdrawal 5 days. Tylosin: 10-20 mg/kg PO, or 100-200 g/ton feed, or 100-200 mg/L water, for 3-5 days; withdrawal 3 days. Tilmicosin: 15-20 mg/kg PO, or 200-400 g/ton feed, or 200-400 mg/L water, for 3-5 days; withdrawal 14 days. Enrofloxacin: 10 mg/kg PO, or 100-200 g/ton feed, or 100-200 mg/L water, for 3-5 days; withdrawal 10 days (check local regulations). Florfenicol: 20-30 mg/kg PO, or 200-400 g/ton feed, or 200-400 mg/L water, for 3-5 days; withdrawal 14 days. Supportive vitamins: Vitamin A (10,000-20,000 IU/L water), Vitamin D3 (2,000-4,000 IU/L), Vitamin E (100-200 IU/L), Vitamin C (100-200 mg/L), Vitamin K (10-20 mg/L) for 3-5 days. Electrolytes: 0.5-1% glucose and electrolytes in water for 3-5 days. Vaccines: Live or inactivated E. coli vaccines are available in some regions; administer per manufacturer's instructions, typically at 1 day of age (live) or 16-18 weeks (inactivated).

Landmark studies and consensus guidelines: 1) The AAAP's Avian Disease Manual provides comprehensive guidelines on diagnosis and treatment of colibacillosis. 2) Studies by Nolan et al. (2013) and Johnson et al. (2008) have characterized APEC virulence factors and pathogenesis. 3) Clinical trials by Vandemaele et al. (2002) demonstrated the efficacy of autogenous vaccines in reducing colibacillosis in broilers. 4) Meta-analyses by Gunawardana et al. (2014) have shown that antimicrobial therapy is effective when based on sensitivity testing. 5) The World Organisation for Animal Health (WOAH/OIE) provides guidelines for antimicrobial use and resistance monitoring. 6) Expert consensus from the WVPA emphasizes the importance of biosecurity and management in controlling colibacillosis. 7) Research by Dho-Moulin and Fairbrother (1999) reviewed the pathogenesis and prevention of avian colibacillosis. 8) Recent studies on antimicrobial resistance, such as those by Mellata (2013), highlight the need for prudent antibiotic use and alternative strategies like probiotics and bacteriophages.